-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III

Symposia: Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Program: Oral and Poster Abstracts
Type: Poster
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Hoang Thao Giang Nguyen1*, Van Quan Nguyen2*, Dang Xuan Tran2*, Akiyoshi Takami, MD, PhD3 and J. Luis Espinoza, MD, PhD4*

1Graduate School of Medical Sciences, Kanazawa University, Kanazawa, ISH, Japan
2Graduate School of Advanced Science and Engineering, Hiroshima University, Higashi-Hiroshima City, Hiroshima, Japan
3Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan
4Faculty of Health Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan

Amar Hadzic, MSc1,2,3*, Maria Garcia-Marquez, PhD4,5*, David M. Cordas dos Santos, MD1,3,6*, Martin E. Kirmaier, PhD1,3,6*, Pol Bannasch, MSc1,6*, Nina Haindl, MSc1,6*, Sabine Oganesian, MSc1,3,6*, Maximilian A Funk, MD, PhD1,3,6*, Anneli Tischmacher, BSc1,6*, Katharina Frey, MSc1,6*, Ludovica Vona1,3,6*, Adriano Carboniero, MSc1,3,6*, Jingke Tu, MD1,3,6*, Michael Von Bergwelt, MD, PhD1,3,6,7,8 and Sebastian Theurich, MD1,3,6,7,8*

1Department of Medicine III, University Hospital Munich (LMU), Munich, Germany
2Cancer- and Immunometabolism Research Group, LMU Gene Center, München, Germany
3German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
4Department of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Cologne, Germany
5Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
6Cancer- and Immunometabolism Research Group, LMU Gene Center, Munich, Germany
7Bavarian Cancer Research Center (BZKF), Munich, Germany
8Comprehensive Cancer Center Munich, LMU University Munich, Munich, Germany

Tiffany Hangse1, Shalini Pullarkat2*, Aaron Boothby, MD3, Olga Sala Torra, MD2*, Lan W. Beppu2*, Sophie H.R. Storz4*, Miranda P.G. Zalusky4*, Danny Miller, MD, PhD4,5,6*, Maite de la Morena, MD4*, Cecilia C.S. Yeung, MD2,6,7, Sandhya Panch, MD MPH8* and Eric Allenspach, MD, PhD4,9*

1Western Michigan University Homer Stryker School of Medicine, Kalamazoo, MI
2Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
3University of Washington/Fred Hutchinson Cancer Center, Saint Paul, MN
4Department of Pediatrics, University of Washington, Seattle, WA
5Brotman Baty Institute for Precision Medicine, University of Washington, Seattle, WA
6Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA
7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
8University of Washington/Fred Hutchinson Cancer Center, Seattle, WA
9Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA

Kameron Allen Kooshesh, MD, BA1,2,3,4, Karin Gustafsson, PhD1,2,3,4*, Brody Foy, DPhil5 and David Scadden, MD1,2,3,4

1Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA
2Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA
3Harvard Stem Cell Institute, Cambridge, MA
4Harvard Medical School, Boston, MA
5Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA

Vinothkumar Rajan, PhD, Christina R Lee* and Juan Carlos Zuniga-pflucker, Ph.D*

Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada

Maryam Kazerani, PhD1, Simeon Mahov1*, Joslyn Foley1*, Noah Merin, MD, PhD1, So Yung Choi2*, Joseph Lownik, MD, PhD3, Alexander Xu, PhD1*, Larry Milshteyn, BS1*, Anton Luis Villamejor1*, Maimoona Nadri4*, Nathalie Nguyen4*, Omid Hamid, MD4,5*, Justin M. Darrah, MD1*, Jun Gong4*, Ronald Paquette, MD1, Alain Mita4*, Robert Allen Vescio, MD1, Inderjit Mehmi5*, Warren Tourtellotte3,6*, V Krishnan Ramanujan4*, Karen Reckamp4*, Jane Figueiredo4* and Akil Merchant, MD1

1Division of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
2Biostatistics Shared Resource, Cedars-Sinai Medical Center, Los Angeles, CA
3Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
4Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
5The Angeles Clinic & Research Inst., Los Angeles, CA
6Department of Neurology, Neurological Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA

Michael V. Gonzalez1*, Melanie D. Mumau1*, Joseph M. Zinski, PhD1*, Abiola Irvine, BS1*, Joshua D Brandstadter, MD, PhD, MSc1,2, Sheila K. Pierson, MSc1*, Bridget Austin1* and David C. Fajgenbaum, MD3

1Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

Melanie D. Mumau1*, Criswell L. M. Lavery, BS, MPH1*, Abiola Irvine, BS1*, Joseph M. Zinski, PhD1*, M. Betina Pampena, PhD2*, Ira D. Miller, BS1*, Michael V. Gonzalez1*, Michael R. Betts, PhD2* and David C. Fajgenbaum, MD3

1Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3Center for Cytokine Storm Treatment & Laboratory, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

Deborah J. Steiner*, Katrina Adell*, Henry Wu*, Susan Dubuc*, Katherine Carter*, Nour Ziyadeh*, Margo Jaffee*, Xiaoxi Li*, Sam Wilson*, Matthew Dame*, Wendy Magnan* and Christophe Arbet-Engels*

X4 Pharmaceuticals Inc., Boston, MA

*signifies non-member of ASH